Celldex Therapeutics (CLDX) Gross Profit (2010 - 2026)

Celldex Therapeutics' Gross Profit history runs 7 years deep, the most recent figure standing at -$1.4 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 2.04% year-over-year to -$1.4 million in Q1 2026; TTM through Mar 2026 was -$4.4 million, a 506.34% decrease from a year earlier, with the FY2025 full-year figure at -$4.5 million, down 415.97% from the prior year.
• Gross Profit eased to -$1.4 million in Q1 2026 per CLDX's latest filing, from -$1.1 million in the prior quarter.
• Across five years, Gross Profit topped out at $2.1 million in Q3 2024 and bottomed at -$1.5 million in Q1 2025.
• The 3-year median for Gross Profit is -$1.1 million (2025), against an average of -$498333.3.
• Across the five-year window, Gross Profit sank 192.19% in 2025 and gained 2.04% in 2026, its largest moves.
• Year by year, Gross Profit stood at -$439000.0 in 2024, then slumped by 152.16% to -$1.1 million in 2025, then slumped by 30.35% to -$1.4 million in 2026.
• Per Business Quant, the three latest CLDX Gross Profit figures stand at -$1.4 million (Q1 2026), -$1.1 million (Q4 2025), and -$1.1 million (Q3 2025).